TP53 and ovarian cancer: In ovarian cancer cells, cisplatin treatment mediates p53 serine 15 phosphorylation by activating ERK1/2 in response to DDR-induced apoptosis, whereas the selective MEK1 inhibitor PD98059 reduces p53 serine 15 phosphorylation and apoptosis [200].